Annual industry ranking and forecast
Exclusive interviews with leaders at Pfizer, Sanofi and Johnson & Johnson, as well a deep dive into what nominated FDA commissioner, Robert Califf, might do when taking the helm of the US regulatory agency in 2022.
Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.
The COVID-19 pandemic dealt a blow to Johnson & Johnson’s Vision Care business, but the company maintained its innovation program and kept customer engagement to the fore. It has started to see a return to positive contact lens buying trends, says Vision Care European business leaders Sandra Rasche and Lisa Ann Hill.
Sanofi’s general medicines business will embrace an omnichannel commercial model in 2022 to reduce inefficiencies and stabilize topline growth. Virtual sales reps are on the rise after a tough couple of years managing product promotion and launches online only.
Should Robert Califf gain a second term as US FDA commissioner, he likely will find that many of the issues demanding attention remain the same as when he left the agency five years ago, even though the names of the products now linked with them are different.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.